Skip to content

Released Feb 26, 2026, before the open

10-K filed Feb 26, 2026, 57 days after period end · 0001193125-26-073699

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$1.37Mderived−26.4% vs Q4 2024−21.4% vs Q3 2025
Net Income-$32.37MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$34,721,000N/M
Operating Cash Flowderived-$23,314,000N/M
Free Cash Flowderived-$24,506,000N/M
Margins · derived
Operating margin-2536.2%+783.6 pt vs Q4 2024
Net margin-2364.8%+439.1 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$1.37M$1.86M$1.68M$44.36M
Net Income-$32.37M-$52.15M-$44.12M-$56.36M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR